← Leaderboards
Sam Sunghyun Yoon
Massachusetts General Hospital
$2,703,621
Attributed
$4,770,081
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $539.2K · FY2006–21$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,770,081 · 2
By mechanism
R01$4,132,920 · 1
R21$637,161 · 1
Top collaborators
- M. Celeste Simon11 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jan Patrick Oscar Schuemann$8,838,029
- John M Kyriakis$5,345,121
- Laura Maria Calvi$9,706,127
- Timothy P Padera$10,637,651
- Nathan I Shapiro$5,352,426
Others in their field
Top investigators on “Hypoxia Inducible Factor”
- Sean P Colgan · University Of Colorado Denver$20,259,344
- M. Celeste Simon · University Of Pennsylvania$17,629,315
- Gregg L Semenza · Johns Hopkins University$15,704,252
- Gordon Stewart Mitchell · University Of Florida$15,574,838
- Amato J. Giaccia · Stanford University$14,043,582
- Garth Powis · University Of Arizona$13,333,232
Research focus
Hypoxia Inducible FactorDesignTumorHypoxiaRecurrenceGenesSarcomaSolid NeoplasmMalignant NeoplasmsResearch ProposalsPersonsDistant MetastasisPlayPhenotypePreventResistanceMouse ModelMediatingNeoplasm MetastasisCell LineMigrationCell ProliferationAffectGenetic Transcription
Grant awards (13)
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis$532,662
R01 · FY2021 · CA
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis$463,845
R01 · FY2020 · CA
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis$75,365
R01 · FY2020 · CA
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis$456,218
R01 · FY2019 · CA
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis$476,652
R01 · FY2018 · CA
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis$498,058
R01 · FY2017 · CA
HIFs and VEGF in sarcoma progression, metastasis, and radiation response$332,000
R01 · FY2015 · CA
HIFs and VEGF in sarcoma progression, metastasis, and radiation response$322,040
R01 · FY2014 · CA
HIFs and VEGF in sarcoma progression, metastasis, and radiation response$312,080
R01 · FY2013 · CA
HIFs and VEGF in sarcoma progression, metastasis, and radiation response$332,000
R01 · FY2012 · CA
HIFs and VEGF in sarcoma progression, metastasis, and radiation response$332,000
R01 · FY2011 · CA
Bevacizumab and radiation therapy for sarcomas$308,544
R21 · FY2007 · CA · contact PI
Bevacizumab and radiation therapy for sarcomas$328,617
R21 · FY2006 · CA · contact PI